Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ABNX.PA
- Price
- 3.72
- Stock movement down
- -0.01 (-0.27%)
- Company name
- Abionyx Pharma SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 130.00M
- Ent value
- 134.19M
- Price/Sales
- 14.08
- Price/Book
- 24.01
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 190.16%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2026-01-12
DIVIDENDS
ABNX.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 14.08 |
| Price to Book | 24.01 |
| EV to Sales | 14.54 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 35.28M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -0.47 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 3.38M |
| Net receivables | 1.69M |
| Total current assets | 5.45M |
| Goodwill | 5.38M |
| Intangible assets | 71.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 12.98M |
| Accounts payable | 1.26M |
| Short/Current long term debt | 4.12M |
| Total current liabilities | 3.88M |
| Total liabilities | 7.56M |
| Shareholder's equity | 5.41M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.68 |
| Daily high | 3.79 |
| Daily low | 3.67 |
| Daily Volume | 117K |
| All-time high | 14.14 |
| 1y analyst estimate | 10.50 |
| Beta | 0.94 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 4 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ABNX.PA | S&P500 | |
| Current price drop from All-time high | -73.69% | -0.50% |
| Highest price drop | -92.01% | -19.00% |
| Date of highest drop | 7 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -85.53% | -2.50% |
| Avg time to new high | - | 6 days |
| Max time to new high | 320 days | 89 days |
COMPANY DETAILS
Marketcap
130.00M
Marketcap category
Small-cap
Description
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis (NASH). The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is headquartered in Balma, France.
Employees
51
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
TOULOUSE, France, January 07, 2026--Regulatory News: Under the liquidity contract covering ABIONYX Pharma shares (FR0012616852 – ABNX FP) entrusted to TP ICAP (Europe), the following assets were inclu...
January 7, 2026
The European market has recently shown signs of steady economic growth, with major stock indexes rising and the pan-European STOXX Europe 600 Index ending 1.60% higher. This positive momentum, coupled...
December 25, 2025
TOULOUSE, France & FULLERTON, Calif., December 17, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era...
December 17, 2025
TOULOUSE, France & FULLERTON, Calif., December 16, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era...
December 16, 2025
TOULOUSE, France, December 05, 2025--Regulatory News: ABIONYX Pharma (Paris:ABNX):
December 5, 2025
TOULOUSE, France & FULLERTON, Calif., November 25, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), ), a next-generation biopharma company pioneering a new therapeutic ...
November 25, 2025
TOULOUSE, France & FULLERTON, Calif. & LISSES, France, November 20, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a ne...
November 20, 2025
TOULOUSE, France & FULLERTON, Calif., November 12, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era...
November 12, 2025
TOULOUSE, France & FULLERTON, Calif., November 12, 2025--ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved dis...
November 12, 2025
TOULOUSE, France & FULLERTON, Calif., October 21, 2025--ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, tod...
October 21, 2025
Next page